Indanyloxyphenylcyclopropanecarboxylic acids
AssigneeBoehringer Ingelheim International GmbH
InventorsDieter Hamprecht, Sara Frattini, Iain Lingard, Stefan Peters
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of general formula I, wherein the groups R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
Claims17
A compound of formula (I)
- wherein:
- R1 is selected from the group R1-G1 consisting of a phenyl ring, a tetrazolyl ring,
- a 5-membered heteroaromatic ring containing 1 —NH—, or —S— group,
- a 5-membered heteroaromatic ring containing 1 —NH—, or —S— group and additionally 1 or 2 ═N— atoms,
- a 6-membered heteroaromatic ring containing 1, 2 or 3 ═N— atoms,
- wherein:
- optionally a second ring is annulated to the phenyl ring or to the 5- or 6-membered heteroaromatic rings and the second ring is 5- or 6-membered, unsaturated or aromatic and may contain 1, 2, or 3 heteroatoms independently selected from ═N—, —NH—, and —S— with the proviso that only up to two of the heteroatoms are O and S and no O—O, S—S, and S—O bond is formed, and wherein in the second ring independently of the presence of heteroatoms 1 or 2 CH2 groups are optionally replaced by —C(O)—, —S(O)—, or —S(O)2—,
- the phenyl ring, tetrazolyl ring, 5- or 6-membered heteroaromatic ring, annulated phenyl ring, and annulated 5- or 6-membered heteroaromatic ring are optionally substituted at a carbon atom with one group R1a,
- the phenyl ring, tetrazolyl ring, 5- or 6-membered heteroaromatic ring, annulated phenyl ring, and annulated 5- or 6-membered heteroaromatic ring are optionally additionally substituted at carbon atoms with 1 to 3 groups independently selected from R1b, and
- wherein the H-atom in one or more NH groups present in the tetrazolyl ring, 5- or 6-membered heteroaromatic ring, annulated phenyl ring, or annulated 5- or 6-membered heteroaromatic ring optionally is replaced by RM,
- H, F, Cl, Br, I, NC—, C1-8-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-8-cycloalkyl, C3-8 cycloalkyl C1-4-alkyl, C5-12-bicycloalkyl-, C5-6-cycloalkenyl, C5-6-cyclo C1-8-alkyloxy, C3-6-cycloalkyl-oxy, C3-6-cycloalkyl-C1-4-alkyloxy, —NHRN, HNRM—C(O)—, C1-4-alkyl-NRM—C(O)—, wherein any of the saturated and unsaturated aliphatic and carbocyclic groups and submoieties within the groups mentioned are optionally independently substituted with one or more F atoms and/or 1 to 3 R1c groups,
- R2 is selected from the group R2-G1 consisting of F, Cl, Br, I, C1-4-alkyl, C3-6-cycloalkyl, NC—, H2N—C(O)—, C1-4-alkyl-NRM—C(O)—, HO—C(O)—, C1-4-alkyl-O—C(O)—, C1-4-alkyloxy, and C1-4-alkyl-S(O)2—, wherein any alkyl and cycloalkyl group or sub-group within the groups mentioned is optionally substituted with one or more F atoms, and wherein multiple R2 are identical or different, if m is 2 or 3;
- R3 is selected from the group R3-G1 consisting of F, Cl, Br, I, NC—, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-6-cycloalkyl-, C1-4-akyl-NH—, (C1-4-alkyl)2N—, C1-6-alkyl-O—, C3-6-cycloalkyl-O—, C1-4-alkyl-S—, C1-4-alkyl-S(O)—, and C1-4-alkyl-S(O)2, wherein each alkyl and cycloalkyl group and each alkyl and cycloalkyl sub-group within the groups mentioned is optionally substituted with 1 or more F atoms;
- m is 0, 1, 2, and or 3;
- n is 0, 1, 2, and or 3;
- R1a is selected from the group R1a-G1 consisting of
- C1-6 alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-6-cycloalkyl-, C3-6-cycloalkyl-C1-6-alkyl, C1-4-alkyl-NH—, (C1-4-alkyl)2N—, —NHRN, HNRM—C(O)—, C1-4-alkyl-NRM—C(O)—, C1-6-alky-O—, C3-6-cycloalkyl-O—, C3-6-cycloalkyl-C1-6-alkyl-O—, C1-4-alkyl-S—, C1-4-alkyl-S(O)—, and C1-4-alkyl-S(O)2,
- wherein:
- a —CH2— member within a C4-6-cycloalkyl- group or sub-group within the groups mentioned optionally is replaced by —NRN—, —O—, —S—, —S(O)—, or —S(O2)—, or
- a >CH—CH2— member or a —CH2—CH2— member within a C5-6-cycloalkyl- group or sub-group within the groups mentioned optionally is replaced by >N—C(O)—, >N—S(O)—, >N—S(O)2—, —N(RM)—C(O)—, —N(RM)—S(O)—, or —N(RM)—S(O)2—, and
- each alkyl and cycloalkyl group and each alkyl and cycloalkyl sub-group within the groups mentioned optionally is substituted with HO—, HO—C1-4-alkyl-, C1-4-alkyl-oxy, C1-4-alkyl-oxy-C1-4-alkyl-, C1-4-alkyl-sulfanyl, C1-4-alkyl-sulfinyl, C1-4-alkyl-sulfonyl, H2N—C(O)—, C1-4-alkyl-NH—C(O)—, (C1-4-alkyl)2N—C(O)—, or C3-6-cycloalkyl-NRM—C(O)— and/or optionally substituted with 1 or more F atoms;
- a phenyl ring, a tetrazolyl ring,
- a 5-membered heteroaromatic ring containing 1 —NH—, —O—, or —S— group,
- a 5-membered heteroaromatic ring containing 1 —NH—, —O—, or —S— group and additionally 1 or 2 ═N— atoms,
- a 6-membered heteroaromatic ring containing 1, 2, or 3 ═N— atoms,
- wherein the rings are optionally substituted with one or more groups selected from R1b;
- and
- wherein the H-atom in one or more NH groups present in the tetrazolyl ring or 5-membered heteroaromatic ring is replaced by RM,
- R1b is selected from the group R1b-G1 consisting of F, Cl, Br, I, CN, —OH, C1-4-alkyl, C3-6-cycloalkyl-, HO—C1-4-alkyl, C1-4-alkyl-O—C1-4-alkyl, —NRNH, C1-4-alkyl-NRN—, C1-4-alkyl-O—, C3-6-cycloalkyl-O—, C1-4-alkyl-O—C1-4-alkyl-O—, C1-4-alkyl-S—, C1-4-alkyl-S(O)—, and C1-4-alkyl-S(O)2—, wherein any alkyl and cycloalkyl group or sub-group within the groups mentioned is optionally substituted with 1 or more F atoms;
- R1c is selected from the group R1c-G1 consisting of F, Cl, Br, I, CN, —OH, C1-3-alkyl, HO—C1-3-alkyl, C1-4-alkyl-O—, and C1-3-alkyl-O—C1-3-alkyl, wherein any alkyl group or sub-group within the groups mentioned is optionally substituted with 1 or more F atoms;
- and
- RN is independently selected from the group RN-G1 consisting of H, C1-4-alkyl, HO—C2-4-alkyl (with the proviso that at least 2 carbon atoms are between the HO-group and an NH), C1-4-alkyl-O—C2-4-alkyl- (with the proviso that at least 2 carbon atoms are between an O-group and an NH), C1-4-alkyl-C(O)—, C1-4-alkyl-O—C(O)—, and C1-4-alkyl-S(O)2, wherein any alkyl group or sub-group within the groups mentioned is optionally substituted with 1 or more F atoms;
- RM is independently selected from the group RM-G1 consisting of H, C1-4 alkyl, HO—C2-4-alkyl (with the proviso that at least 2 carbon atoms are between the HO-group and an NH), and C1-4-alkyl-O—C2-4-alkyl- (with the proviso that at least 2 carbon atoms are between an O-group and an NH), wherein any alkyl group or sub-group within the groups mentioned is optionally substituted with 1 or more F atoms;
- wherein in any definition mentioned hereinbefore and if not specified otherwise, any alkyl group or sub-group may be straight-chained or branched, or a salt thereof.
A compound compound of formula
- in racemic form, or the following enantiomers thereof
- wherein R4 is C1-4-alkyl or phenyl-CH2—.
A process for the preparation of an intermediate of formula XVa or XVb via intermediates XIVa or XIVb, comprising reacting 4-tert-butyloxystyrene with a diazo acetate ester following the reaction scheme
- wherein R4 is C1-4-alkyl or phenyl-CH2—, in the presence of a catalyst, and the resulting compounds of formula XVa or XVb are obtained in enantiomerically enriched form.
Dependencies are inferred from the claim text.